Inside the body with BPC-157

BPC-157 is described as a 15-residue fragment of a larger gastric-juice protein (body protection compound), first characterised in Croatia in the early 1990s. The earliest work is in rodents: it reduced stomach and small-intestine lesions after high-dose NSAIDs by over 75% by macroscopic size, and it improved healing of surgically made colonic fistulas in rats. FDA reviewers noted that no dose-response relationship was found in these studies and that the fistula and NSAID-lesion studies did not report tissue histology. It was not found to change gastric acid secretion or gut motility.[src][src]

After IV dosing the elimination half-life is 5.3 minutes in beagle dogs and 15.2 minutes in rats; exposure is linear across intramuscular doses, with intramuscular bioavailability of about 14-19% in rats and 45-51% in dogs. Tritium-labelled peptide was rapidly cleaved into small peptide fragments and single amino acids that enter normal amino-acid metabolism, with excretion mainly in urine and bile. Human pharmacokinetics are unreported; FDA notes that it does not appear to be absorbed systemically after a rectal enema.[src][src]

In the chick chorioallantoic membrane assay, the endothelial tube-formation assay and rat hind-limb ischaemia, BPC 157 increased vessel density and accelerated blood-flow recovery. In human endothelial cells it raised VEGFR2 expression (not VEGF-A), promoted VEGFR2 internalisation and time-dependently activated VEGFR2-Akt-eNOS signalling; blocking endocytosis with dynasore suppressed these effects. The study did not show that BPC 157 binds VEGFR2 directly.[src][src]

In residual internal mammary artery rings from 12 coronary bypass patients, BPC 157 produced concentration-dependent relaxation of phenylephrine-contracted rings, greater in endothelium-intact rings, and the effect was attenuated by the NOS inhibitor L-NAME, pointing to an endothelium-dependent nitric oxide pathway with residual NO-independent effects. This is ex vivo human tissue, not in vivo evidence. FDA reviewers list stimulation of nitric oxide synthesis among researchers' hypotheses from rodent work, but note that the mechanisms remain poorly understood.[src][src]

In rat Achilles tendon explants and fibroblasts, BPC 157 accelerated outgrowth, increased cell survival under H2O2 stress and dose-dependently increased migration, with increased phosphorylation of FAK and paxillin; it did not directly increase proliferation. A separate cDNA microarray study found growth hormone receptor among the most up-regulated genes, with JAK2 activation on adding growth hormone. A systematic review of the musculoskeletal literature (35 preclinical studies) reports improved functional and biomechanical outcomes in tendon, ligament, muscle and bone injury models, all of it animal data.[src][src][src]

In rat models (bile duct and hepatic artery ligation, restraint stress, carbon tetrachloride, repeated diclofenac), BPC-157 given orally or intraperitoneally reduced liver necrosis and enzyme rises. FDA reviewers noted that the protective effect was similar at both tested doses (no dose-response), and that treatment after injury had not been tested in these models.[src]

FDA's 2026 evaluation states that molecular targets have not been identified, dose-response relationships have not been established for the reported gastrointestinal and hepatic effects, and the mechanisms remain poorly understood, which makes biological plausibility difficult to judge. A 2025 independent review describes the human evidence as three small pilot studies and says BPC-157 should be considered investigational.[src][src]